News

Press Releases

May 18, 2017: Magenta Therapeutics Selected as “Hottest Early Stage Startup” in Healthcare in New England Venture Capital Association’s 2017 NEVY Awards

May 10, 2017: Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting (Business Wire)

May 2, 2017: Magenta Therapeutics Advances Stem Cell Transplantation Strategy with  $50 Million Series B Financing, Licensing of Clinical-Stage Stem Cell Expansion Program and Strategic Partnership with Be The Match BioTherapies

December 2, 2016: Magenta Therapeutics Cofounder David Scadden Honored at the American Society of Hematology Annual Meeting, as Scientific Founders Present New Stem Cell Biology Data

November 16, 2016: Magenta Therapeutics Announces $48.5M Series A Financing to Transform Stem Cell Transplant for Immune and Blood Diseases

 

Magenta In The News

May 3, 2017: Magenta Therapeutics gets $50 million in funding (Boston Globe)

May 2, 2017: Building a biotech: Magenta opens up Chapter 2 with a triple play (Blog post by Jason Gardner @ LifeSciVC.com)

Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it (Endpoints News)

Magenta Nabs More Cash, Licenses Drug To Boost Transplant Pipeline (Xconomy)

A $50 Million Bet on Stem-Cell Therapy (Wall Street Journal Venture Capital Pro)

Magenta gains $50M Series B, Novartis candidate and new partnership (FierceBiotech)

April 11, 2017: Magenta named one of Nature Biotechnology’s top academic spinouts of 2016 (Nature Biotechnology)

November 16, 2016: Rebooting The Conversation (Blog post by Jason Gardner @ LifeSciVC.com)

Atlas, Third Rock join forces to launch new stem cell upstart (FierceBiotech)

Harvard Spinout Magenta, Other Academics Race Toward Better Stem Cell Transplants (Xconomy)

Stem Cell Transplant Startup With Harvard Tech, Magenta Therapeutics, Gets $48.5M (Forbes)

 

» Read all the recent news about Magenta here